Comparison of the efficacy of Lu-177-EDTMP, Lu-177-DOTMP and Re-188-HEDP towards bone osteosarcoma: an in vitro study

摘要

Among the radiopharmaceuticals harnessed for palliation of bone pain in osseous metastases patients, Lu-177 labeled phosphonates such as EDTMP (Ethylene diamine tetramethylene phosphonic acid) as well as DOTMP (1,4,7,10-tetraaza-cyclo-dodecane-1,4,7,10 tetraethylene phosphonic acid) and Re-188-labeled HEDP (1,1-hydroxyethylene diphosphonic acid) seem to be the most favorable for treatment of small and medium/large size bone lesions, respectively. A comparative assessment of Lu-177-EDTMP, Lu-177-DOTMP and Re-188-HEDP in osteosarcoma tumor cell line was carried out to evaluate their relative efficacy. It was found that Re-188-HEDP is more potent in induction of cell toxicity and apoptosis compared to the Lu-177-EDTMP and Lu-177-DOTMP, thus Re-188-HEDP might have great clinical significance.